Patents by Inventor Ian W. Davies

Ian W. Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10394482
    Abstract: Systems and methods for replicating a snapshot of a volume are described. In one embodiment, a storage controller of a storage system may be operable to initialize a first replication process between a first storage volume of the first storage system and a second storage volume of a second storage system, copy content from a first system snapshot of the first storage volume to a second system snapshot of the first storage volume, and copy content from a first user snapshot of the first storage volume to the first system snapshot of the first storage volume. In some cases, a system snapshot is not accessible to a user and a user snapshot is accessible to the user. In some cases, at least one of the system snapshot and the user snapshot include a point in time capture of data on the first storage volume.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: August 27, 2019
    Assignee: SEAGATE TECHNOLOGY LLC
    Inventors: Douglas W. Dewey, Kenneth F. Day, Ian R. Davies
  • Patent number: 9512426
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: December 6, 2016
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Publication number: 20150132761
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 14, 2015
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Patent number: 8877439
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: November 4, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Publication number: 20120252027
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Application
    Filed: December 9, 2010
    Publication date: October 4, 2012
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Patent number: 6800647
    Abstract: This invention encompasses a pharmaceutical composition comprising the compound of formula A: in combination with a pharmaceutically acceptable carrier, said compound being comprised of about 1-50%, 1-20% or 1-10% of the polymorphic form which is designated Form V and the remainder of the compound being comprised of at least one polymorphic form selected from the group consisting of: Form I, Form II, Form III and Form IV.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: October 5, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Loius S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6673935
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: January 6, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Publication number: 20030153600
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1
    Type: Application
    Filed: January 14, 2003
    Publication date: August 14, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6521642
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: February 18, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Publication number: 20020147221
    Abstract: This invention encompasses a pharmaceutical composition comprising the compound of formula A: 1
    Type: Application
    Filed: September 21, 2001
    Publication date: October 10, 2002
    Inventors: Loius S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6369275
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: April 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Publication number: 20020016343
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1
    Type: Application
    Filed: May 25, 2001
    Publication date: February 7, 2002
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6281391
    Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 28, 2001
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski
  • Patent number: 6252116
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: June 26, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Edward G. Corley, Ian W. Davies, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6204387
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: March 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Linda Gerena, Michel Journet, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6040319
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Edward G. Corley, Ian W. Davies, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6040450
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen